eNOS Gene Polymorphısms And Transıtıonal Cell Cancer Of The Bladder

Emre, Fatma Sinem Hocaoğlu; Toker, Aziz; Erkan, Erkan; Yücetaş, Uğur

eNOS Gene Polymorphısms And Transıtıonal Cell Cancer Of The Bladder

dc.authorid	262746	en_US
dc.contributor.author	Emre, Fatma Sinem Hocaoğlu
dc.contributor.author	Toker, Aziz
dc.contributor.author	Erkan, Erkan
dc.contributor.author	Yücetaş, Uğur
dc.date.accessioned	2021-01-22T09:07:10Z
dc.date.available	2021-01-22T09:07:10Z
dc.date.issued	2020
dc.department	İstanbul Beykent Üniversitesi	en_US
dc.description.abstract	Aim: In this case-control study, we examined the association between two types of eNOS gene polymorphisms (intron 4 a/b and Glu298Asp) and transitional cell carcinoma (TCC) of the bladder. Nitric Oxide (NO) is a free radical that plays a key role in various physiological and pathophysiological processes, particularly in the circulatory system. Endothelial Nitric Oxide Synthase (eNOS), as a member of NOS family, is the enzyme, responsible for the physiological production of nitric oxide in the endothelium. Polymorphisms of eNOS have been related to increased risk for different types of cancers. Material and Methods: A total of 64 patients with bladder TCC and 80 controls with similar epidemiological characteristics of patients group were evaluated and compared in terms of eNOS gene polymorphisms of two different types ((intron 4 a/b and Glu298Asp). Following DNA isolation from the blood samples, eNOS gene was replicated via PCR. The genomic distribution of two types of eNOS polymorphism was determined by gel electrophoresis following the process of restriction, for both groups. Results: The alleles most commonly observed in patient group were “ab” for intron 4 (OR= 1.80, 95% CI: 0.71-4.64; P=0.20) and “GT” for Glu298Asp polymorphisms (OR= 1.65, 95% CI: 0.85-3.22; P=0.14). Neither bladder cancer risk nor disease grade was associated with these polymorphisms. Conclusions: This study suggests that the intron 4 a/b and Glu298Asp eNOS gene polymorphisms are not associated with bladder cancer susceptibility. However, it is mandatory to conduct further trials with more patients to confim these fidings and to evaluate the association between bladder cancer and eNOS gene polymorphisms.	en_US
dc.identifier.citation	Ann Med Res 2020;27(7):2004-10	en_US
dc.identifier.doi	10.5455/annalsmedres.2020.01.039
dc.identifier.issn	2618-6322
dc.identifier.trdizinid	371091	en_US
dc.identifier.uri	https://search.trdizin.gov.tr/yayin/detay/371091
dc.identifier.uri	https://doi.org/10.5455/annalsmedres.2020.01.039
dc.indekslendigikaynak	TR-Dizin	en_US
dc.language.iso	en	en_US
dc.publisher	İnönü Üniversitesi Tıp Fakültesi	en_US
dc.relation.publicationcategory	Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı	en_US
dc.subject	Bladder cancer	en_US
dc.subject	Glu298Asp polymorphism	en_US
dc.subject	İntron 4 a/b polymorphism	en_US
dc.subject	Nitric oxide synthase	en_US
dc.subject	Nitric oxide synthase polymorphism	en_US
dc.title	eNOS Gene Polymorphısms And Transıtıonal Cell Cancer Of The Bladder	en_US
dc.type	Article	en_US